Novo Nordisk stock falls after 2030 growth targets disappoint

Published on 09/21/2026 at 19:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novo Nordisk stock fell 7.65 percent to DKK 260.00 on September 21, 2026, after Capital Markets Day targets left growth vague. Goldman Sachs kept a Neutral rating at DKK 285.

Sterile Fertigungslinie für Insulin-Pens in moderner Pharma-Produktionsanlage — Novo Nordisk A/S (ISIN DK0060534915) produziert Insulin-Pens in modernster steriler Fertigungsanlage mit Robotertechnik effizient, Illustration mit AI erstellt.

Novo Nordisk stock (ISIN DK0060534915) fell to DKK 260.00 on September 21, 2026, after the company used its Capital Markets Day to frame 2026 to 2030 revenue growth as in line with selected industry peers and to keep operating margins broadly stable. The move left the shares 7.65 percent lower on the Nasdaq Copenhagen close and well below the average analyst target of DKK 310.17.

Capital Markets Day sets the tone

As Investing.com reported on September 21, 2026, the company said revenue growth from 2026 to 2030 should track industry peers, while operating margin is expected to stay broadly stable. That message mattered because the market had already pushed the shares down to DKK 260.00, compared with the last close at DKK 281.55.

As MarketScreener summarized on September 21, 2026, the shares were quoted at DKK 260.00 at the close, down 7.65 percent on the day and 20.06 percent year to date. The same report showed analyst consensus at Hold, with 24 analysts and a mean target of DKK 310.17.

Analysts stay split

According to MarketScreener, UBS kept Novo Nordisk at Neutral with a DKK 332 target on September 17, 2026, while Morgan Stanley cut the stock to Underweight with a DKK 250 target on September 11, 2026. Goldman Sachs also kept a Neutral rating with a DKK 285 target, according to MarketScreener on September 21, 2026.

The spread is wide: the same consensus page listed a low target of DKK 203.00 and a high target of DKK 457.00, with 24 analysts in the sample. For investors, that gap matters more than the broad Hold label.

Price versus targets

The stock closed at DKK 260.00 on September 21, 2026, versus a 52-week range that investors typically track alongside the DKK 310.17 average target. The gap to Goldman Sachs at DKK 285.00 is modest, but the gap to the UBS target at DKK 332.00 is larger.